Pharmacy benefit managers are combating President Donald Trump’s administration’s efforts to end drug rebates, according to a Washington Examiner report.
The Pharmaceutical Care Management Association (PCMA) said in a report released Wednesday that drugmakers are to blame for the nation’s rising drug costs, not PBMs. The Trump administration has claimed PBMs are a significant driver of high prices.
According to the Examiner report, the administration says the current rebate system incentivizes high list prices since the PBM earns a percentage of that rebate.
PCMA, however, says list prices are on the rise regardless of whether the PBMs receive rebates.
Click here to read the full report on the Washington Examiner.
